[an error occurred while processing this directive] | [an error occurred while processing this directive]
Retrospective clinical study of simultaneous reduced dose in clinical target volume of radical intensity-modulated radiotherapy for treatment of stage Ⅲ non-small-cell lung cancer
Department of Radiation Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,China
Abstract Objective To evaluate the efficacy and adverse effects of radical intensity-modulated radiotherapy (IMRT) with simultaneous reduced dose in clinical target volume (CTV) for inoperable stage Ⅲ non-small cell lung cancer (NSCLC). Methods A retrospective analysis was performed on a total of 70 patients with stage Ⅲ NSCLC who were admitted to our hospital from 2010 to 2014. All patients received simultaneous reduced-dose IMRT with a prescribed dose of 60 Gy in 30 fractions or 60.2 Gy in 28 fractions for primary gross tumor volume (PGTV, expansion of gross tumor volume by 0.5 cm) and a prescribed dose of 54 Gy in 30 fractions or 50.4 Gy in 28 fractions for planning target volume (PTV). In the 70 patients, 40 received neoadjuvant chemotherapy prior to radiotherapy, 50 concurrent chemoradiotherapy, and 25 adjuvant chemotherapy after radiotherapy. Short-term treatment outcomes and adverse reactions were evaluated. The Kaplan-Meier method was used for survival analysis. Results The median follow-up time was 42.8 months (16.9-68.3 months). The short-term response rate (complete response (CR) plus partial response (PR)) was 81.4%. The CR, PR, stable disease, and progressive disease rates were 7%(5/70), 74%(52/70), 13%(9/70), and 6%(4/70), respectively. In all patients, the median survival time was 26.6 months (5.2-68.3 months). The 2-year overall survival, local recurrence-free survival, and progression-free survival rates were 55%, 68%, and 45%, respectively. In all patients, 9%(6/70) had grade ≥3 radiation pneumonitis, 4%(3/70) grade ≥3 oesophagitis, and 7%(5/70) grade ≥3 myelosuppression. Conclusions IMRT with simultaneous reduced dose in CTV is effective for stage Ⅲ NSCLC. It deserves further prospective studies with large sample sizes.
Corresponding Authors:
Wang Ping,Email:tjdoctorwang@163.com
Cite this article:
Chen Xiuli,Liu Ningbo,Ji Kai et al. Retrospective clinical study of simultaneous reduced dose in clinical target volume of radical intensity-modulated radiotherapy for treatment of stage Ⅲ non-small-cell lung cancer [J]. Chinese Journal of Radiation Oncology, 2016, 25(7): 686-689.
Chen Xiuli,Liu Ningbo,Ji Kai et al. Retrospective clinical study of simultaneous reduced dose in clinical target volume of radical intensity-modulated radiotherapy for treatment of stage Ⅲ non-small-cell lung cancer [J]. Chinese Journal of Radiation Oncology, 2016, 25(7): 686-689.
[1]Bradley JD,Paulus R,Komaki R,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage ⅢA or ⅢB non-small-cell lung cancer (RTOG 0617):a randomised,two-by-two factorial phase 3 study[J].Lancet Oncol,2015,16(2):187-199.DOI:10.1016/S1470-2045(14)71207-0 [2]PL03.05 An intergroup randomized phase Ⅲ comparison of standard-dose (60 Gy) vs. high-dose (74 Gy) chemoradiotherapy (CRT)+/-cetuximab (cetux) for stage Ⅲ non-small cell lung cancer (NSCLC):results on cetux from RTOG 0617[J].Clin Adv Hematol Oncol,2014,12(1 Suppl 1):2-4 [3]Kepka L,Maciejewski B,Withers RH.Does incidental irradiation with doses below 50 Gy effectively reduce isolated nodal failures in non-small-cell lung cancer:dose-response relationship[J].Int J Radiat Oncol Biol Phys,2009,73(5):1391-1396.DOI:10.1016/j.ijrobp.2008.07.070 [4]Goldstraw P,Crowley J,Chansky K,et al. The IASLC lung cancer staging project:proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours[J].J Thorac Oncol,2007,2(8):706-714.DOI:10.1097/JTO.0b013e31812f3c1a [5]Chang JY,Senan S,Paul MA,et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer:a pooled analysis of two randomised trials[J].Lancet Oncol,2015,16(6):630-637.DOI:10.1016/S1470-2045(15)70168-3 [6]Rodrigues G,Oberije C,Senan S,et al. Is intermediate radiation dose escalation with concurrent chemotherapy for stage Ⅲ non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis[J].Int J Radiat Oncol Biol Phys,2015,91(1):133-139.DOI:10.1016/j.ijrobp.2014.09.033 [7]Jiang ZQ,Yang KY,Komaki R,et al. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer:the MD Anderson experience[J].Int J Radiat Oncol Biol Phys,2012,83(1):332-339.DOI:10.1016/j.ijrobp.2011.06.1963 [8]Curran Jr WJ,Paulus R,Langer CJ,et al. Sequential比concurrent chemoradiation for stage Ⅲ non-small cell lung cancer:randomized phase Ⅲ trial RTOG 9410[J].J Natl Cancer Inst,2011,103(19):1452-1460.DOI:10.1093/jnci/djr325 [9]Fournel P,Robinet G,Thomas P,et al. Randomized phase Ⅲ trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer:Groupe Lyon-Saint-Etienne d′Oncologie Thoracique-Groupe Franais de Pneumo-Cancérologie NPC 95-01 Study[J].J Clin Oncol,2005,23(25):5910-5917.DOI:10.1200/JCO.2005.03.070 [10]Wang SL,Liao ZX,Wei X,et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT)[J].Int J Radiat Oncol Biol Phys,2006,66(5):1399-1407.DOI:10.1016/j.ijrobp.2006.07.1337 [11]Liao ZX,Komaki RR,Thames Jr HD,et al. Influence of technologic advances on outcomes in patients with unresectable,locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2010,76(3):775-781.DOI:10.1016/j.ijrobp.2009.02.032 [12]Thames Jr HD,Withers HR,Peters LJ,et al. Changes in early and late radiation responses with altered dose fractionation:implications for dose-survival relationships[J].Int J Radiat Oncol Biol Phys,1982,8(2):219-226.DOI:10.1016/0360-3016(82)90517-X [13]Selek U,Chang JY.Evolution of modern-era radiotherapy strategies for unresectable advanced non-small-cell lung cancer[J].Lung Cancer Manag,2013,2(3):213-225.DOI:10.2217/lmt.13.14 [14]刘志艳,姬凯,刘维帅,等.应用根治性IMRT结合降低预防照射区剂量治疗Ⅲ期SCLC研究[J].中华放射肿瘤学杂志,2014,23(2):123-126.DOI:10.3760/cma.j.issn.1004-4221.2014.02.011.Liu ZY,Ji K,Liu WS,et al. Clinical efficacy of radical intensity-modulated radiotherapy combined with reduction in dose of prophylactic irradiation in treatment of stage Ⅲ small cell lung cancer[J].Chin J Radiat Oncol,2014,23(2):123-126.DOI:10.3760/cma.j.issn.1004-4221.2014.02.011 [15]梁香存,余荣,石安辉,等.Ⅲ期非小细胞肺癌调强放疗省略临床靶区外扩区域的回顾性分析[J].肿瘤,2015,35(6):675-682 Liang XC,Yu R,Shi AH,et al. Retrospective analysis of omitting clinical target volume for patients with stage Ⅲ non-small cell lung cancer treated with intensity-modulated radiotherapy[J].Tumor,2015,35(6):675-682 [16]李建成,陈云萍,黄诚.中晚期非小细胞肺癌肺癌肿瘤是否一定要设置临床靶区[A]//第13届全国肺癌学术大会论文汇编[C].天津:中国抗癌协会,2013.Li JCH,Chen YP,Huang CH.Clinical target area in the middle and late stage non small cell lung cancer[A]//Proceedings of the thirteenth national conference on lung cancer[C].Tianjin:Anti-Cancer Association of China,2013.
2016, Vol. 25 
